Highlights • Deep proteomic profiling reveals mechanistic differences among medulloblastomas • Proteomic-defined SHH subtypes do not differ in RNA expression • MYC phosphorylation events define a higher risk subset of group 3 patients • Inhibiting PRKDC may sensitize MYC-activated…